Boston, MA 06/03/2013 (wallstreetpr) – The share prices of Affymax Inc. (NASDAQ:AFFY) had surged by 32.48 percent to close at $2.08 per share at the end of last trading session. The shares of the company had been trading in the range of $1.55 to $2.10 during the day before closing at $0.51 per share higher than the closing price on previous day. The shares of Affymax Inc. (NASDAQ:AFFY) had recorded $0.78 per share as their 52 week low price level and $27.74 per share as their 52 week high price level of the company.
Affymax Inc. (NASDAQ:AFFY) is a bio pharmaceutical company involved in the development and commercialization of drugs for the treatment of serious life threatening conditions. The recent product candidate of the company, peginesatide, is used for the treatment of anemia in chronic kidney disease patients on dialysis. Affymax Inc. (NASDAQ:AFFY) presently is involved in a worldwide collaboration with Takeda Pharmaceutical Company Limited to develop and commercialize this drug for treatment of anemia.
Affymax Inc. (NASDAQ:AFFY) had recently been gaining heavily on volumes with large number of shares being traded in the market every day. While the average trading volume for the bio pharmaceutical company is at 8.32 million shares per day, Affymax Inc. (NASDAQ:AFFY) had recorded four times this average volume on the last trading session with nearly 35.16 million shares being exchanged hands for the day. This had made the company to enter into NASDAQ volume gainers watch list of market analysts. Affymax Inc. (NASDAQ:AFFY) presently holds 37.49 million shares outstanding with 55 percent of institutional ownership.
